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INTRODUCTION
As the number of long-term survivors of bone marrow
transplantation (BMT) increases, attention must turn to the
late complications of this procedure. One such late compli-
cation is osteoporosis, a decrease in skeletal bone mass. In
the short term, osteoporosis seems trivial compared with a
diagnosis of cancer, but for those cured of their disease, this
condition contributes to chronic morbidity and mort a l i t y.
For example, hip fractures resulting from osteoporosis are
associated with long periods of immobility and restrict the
p a t i e n t ’s lifestyle. Fifty percent of patients who sustain an
o s t e o p o ro s i s - related hip fracture re q u i re assistance with
activities of daily living, and 25% require placement in long-
term care facilities [1]. Osteoporotic hip fractures also affect
patient mortality. Elderly patients who suffer an osteoporo-
s i s - related hip fracture have an increased 1-year mort a l i t y
rate of 12% to 37% [2]. Early recognition and treatment of
osteoporosis should therefore be integral components of the
follow-up of long-term BMT survivors.
DEFINITIONS
Osteopenia is a systemic condition characterized by a
reduced bone mass and increased susceptibility to bone frac-
ture. Osteoporosis is a more severe reduction in bone mass
and a greater susceptibility to bone fracture. These condi-
tions are differentiated by the degree of reduction in bone
mass and can be quantified by T and Z scores. The T score
relates a patient’s bone mass to the peak bone mass of a
healthy young adult. A T score of 0 represents mean peak
adult bone mass, and a T score of –1 represents bone mass
of 1 standard deviation below this mean. Using this scoring
system, osteopenia is defined as a T score between –1 and
–2.5. Osteoporosis is defined as a T score below –2.5. The
Z score is similar to the T score but uses mean bone mass
f rom an age- and sex-matched control as the re f e re n c e
value. T and Z scores can be translated into risk of fracture.
The relative risk of fracture doubles for every standard devi-
ation below adult peak bone mass [3]. Thus, a T score of –1
indicates a 2-fold increase in fracture risk, and a T score of
–2.5 indicates a 5-fold increase in fracture risk.
The actual incidence of fracture depends on the age and
sex of the patient as well as on the bone density. De Laet et
al. [4] related the Z score, age, and sex of the patient to the
incidence of fracture in an elderly Dutch population. Based
on their calculations, a 65-year-old woman with a Z score of
–2.5 had a 1-year risk of hip fracture of 1%. If this patient
maintained the same bone density over time, her 1-year
f r a c t u re risk increased to 5% by 80 years of age. Because
most BMT recipients are under the age of 60, their absolute
risk of fracture is low at the time of initial evaluation. How-
ever, as they age, their fracture risk increases to significant
levels, especially if there is further bone loss.
RISK FACTORS FOR OSTEOPOROSIS
The risk factors for osteoporosis among BMT survivors
can be divided into general risk factors, risks related to the
underlying disease, and risks attributable to the BMT and its
complications (Table 1).
General risk factors for osteoporosis include older age
[5], a thin body habitus [6,7], and a family history of osteo-
p o rosis [8] or low-trauma fractures [7]. Smoking [9,10],
physical inactivity [7], and a diet low in calcium or vitamin
D [7] also reduce bone density.
The patient’s underlying disease can also contribute to
a reduced bone density. For example, multiple myeloma is
associated with systemic osteoporosis as a result of
i n c reased osteoclast activity [11]. In a study of 25 patients
with myeloma [12], 48% had osteoporosis in the lumbar
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spine or femur. Patients with stage III or IV disease had a
lower bone density than those with stage I or II disease. By
multiple re g ression analysis, cumulative prednisone dosage
c o rrelated with decreased bone density. Patients treated for
H o d g k i n ’s disease are also at risk for decreased bone den-
s i t y. In a study of 29 men with a mean age of 35 years
t reated for Hodgkin’s disease with chemotherapy + r a d i a-
tion, the mean Z scores of the lumbar spine and femoral
neck were –0.7 and –0.4, respectively [13]. The exact inci-
dence of osteoporosis is unknown for this group, because
the T scores were not re p o rted. However, 14 of 29 patients
had Z scores less than –1.0 in the femoral neck or lumbar
spine. Decreased bone density also has been re p o rted after
chemotherapy for acute lymphoblastic leukemia [14], and
c h ronic lymphocytic leukemia [15] p robably secondary to
the induction chemotherapy and the prednisone. High
doses of retinoids can induce osteoporosis [16], so patients
t reated with all-trans retinoic acid for acute pro m y e l o c y t i c
leukemia are also probably at risk for decreased bone dens i t y.
Autologous and allogeneic BMT predisposes to the loss
of bone mineral density through both early and late mecha-
nisms. Evidence exists for an immediate effect of the high-
intensity chemotherapy and marrow reinfusion on bone
turnover [17,18]. Serum osteocalcin, a marker of bone for-
mation, is reduced from the day of marrow infusion and
remains low for 12 weeks after BMT [17]. Furt h e rm o re ,
cross-linked type 1 collagen, a marker of bone resorption, is
i n c reased during the first 3 weeks after BMT and re m a i n s
elevated for 12 weeks [17]. The mechanism by which BMT
alters bone metabolism is not entirely clear. Potentially, the
high-intensity chemotherapy associated with transplantation
damages the osteoblasts and their precursors. Alternatively,
the bone loss may be mediated by cytokines released at the
time of transplantation. For example, BMT is known to
stimulate the release of tumor necrosis factor, which inhibits
osteoblasts and stimulates osteoclasts [19,20].
Medications used around the time of BMT also con-
tribute to the early reductions in bone density. Glucocorti-
coids are used in the treatment of acute and chronic graft-
versus-host disease after allotransplantation. In addition,
patients with myeloma, lymphoma, and Hodgkin’s disease
who undergo autotransplantation are likely to have heavy
steroid exposure as part of their induction and salvage regi-
mens. By univariate and multivariate analysis, Ebeling et al.
[21] reported that steroid use before BMT and cumulative
steroid doses after BMT are associated with decreased bone
d e n s i t y. Steroids reduce bone density though multiple
mechanisms. These agents inhibit bone formation by
inhibiting osteoblast function and diff e rentiation of
osteoblast precursors into mature osteoblasts [22,23].
S t e roids also increase bone resorpt ion by incre a s i n g
p a r a t h y roid hormone production, which stimulates osteo-
clast activity [24]. Steroids, by inhibiting luteinizing hor-
mone, follicle-stimulating hormone, and andro s t e n d i o n e
production, inhibit sex hormone production [25].
Cyclosporine, used to treat graft-versus-host disease, is
associated with a reduction in bone mineral density by
decreasing body stores of magnesium [26]. Magnesium is a
major component of bone and is required for the hydroxyla-
tion of vitamin D in the liver.
Administration of granulocyte colony-stimulating factor
(G-CSF) also decreases bone density. Long-term G-CSF
administration can induce osteoporosis in patients with con-
genital neutropenia [27]. Similar results can be seen in
transgenic mice overe x p ressing G-CSF [28]. Short - t e rm
e x p o s u re to G-CSF alters biochemical markers of bone
turnover. Six days of G-CSF administration decreases serum
osteocalcin in BMT patients and marrow donors. Osteocal-
cin levels decline within the first 3 days of G-CSF adminis-
tration and return to normal within 2 days of cessation [29].
In addition to impairing bone formation, short term G-CSF
e x p o s u re also increases bone resorption. Urinary deoxy-
pyridinoline, a marker of bone resorption, is increased from
the first day of G-CSF administration and remains elevated
for 7 days after stopping G-CSF [29]. In mice, 7 days of
G -CSF treatment increases the number of mature osteo-
clasts in bone. Although the short-term exposure to G-CSF
i n c reases bone metabolism, as demonstrated by serum and
urine markers, it is unknown whether these temporary
changes translate into decreased bone density.
The late effects of BMT on bone density are due primar-
ily to gonadal damage caused by the transplant. Alkylating
agents and total-body irradiation used in the high-intensity
regimen before BMT damage the ovaries [30,31] and the
testes [32,33]. As a result of damage to the ovaries, all
women become menopausal immediately after BMT
[30,31,34]. Women who are younger than 25 years at trans-
plantation and who do not receive total-body irradiation are
likely to regain cyclic estrogen secretion after autotransplan-
tation, but all others usually remain menopausal [34]. Thus,
many women are re n d e red permanently menopausal at a
young age and are at risk for significant bone loss.
In the general population, women who become meno-
pausal experience an accelerated rate of bone loss. Bone
mineral density decreases by approximately 5% within the
Table 1 . Risk Factors for Osteoporosis in BMT Patients
General Risk Factors
Older age
Thin body habitus
Family history
Smoking
Physical inactivity
Diet
Underlying Disease
Myeloma
Hodgkin’s disease
Non-Hodgkin’s lymphoma
Acute lymphoblastic leukemia
Chronic lymphocytic leukemia
Acute promyelocytic leukemia
BMT
Early
High-dose chemotherapy
Marrow reinfusion
Medications (glucocorticoids, cyclosporine,
granulocyte colony-stimulation factor)
Late
Hypogonadism
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first 2 years of menopause, but this bone loss can be pre-
vented by hormone replacement therapy [35].
As a result of testicular damage induced by the high-inten-
sity regimen before BMT, men may become deficient in
t e s t o s t e rone. We have re p o rted that 38% of men have
d e c reased testosterone after autotransplantation [36]. The lack
of testosterone produces a decline in bone mass similar to the
loss of estrogen [37]. Unlike our observations in women, the
testicular damage does not appear to be reversible [36].
INCIDENCE OF OSTEOPOROSIS IN BMT SURVIVORS
Several studies have documented the incidence of
osteopenia or osteoporosis after BMT. Many patients have
lost bone density before BMT, but further losses occur after
the transplantation. Valimaki et al. [38] studied 44 adults
(22 women and 22 men) before and after allotransplanta-
tion. The median age of the patients was 40 years. At the
time of initial evaluation before BMT, 39% of patients had
evidence of osteopenia or osteoporosis in the lumbar spine,
and 25% of patients had evidence of osteopenia or osteo-
porosis in the femoral neck. One year after BMT, the per-
centage of patients with osteopenia or osteoporosis in the
lumbar spine or femoral neck increased to 50% and 45%,
respectively. One year after BMT, there was a mean loss of
bone density in lumbar spine and femoral neck of 3.5% and
8%, respectively. Comparable results were obtained by Sul-
livan et al. [39], who studied a similar population.
Castaneda et al. [40] studied bone density in 27 meno-
pausal women a mean of 33.6 months after BMT. The
mean age of the patients was 31.3 years. Fourteen patients
had undergone allotransplantation, and 13 received an
autotransplant. At the time of evaluation, 9 of 27 (33%) had
osteopenia at the lumbar spine, and another 5 of 27 (18%)
had osteoporosis. Only 1 woman received hormone replace-
m e n t therapy (HRT) at the time of evaluation, and none
received calcium or vitamin D supplements. Because bone
density tests were not perf o rmed before transplantation, it
is not known how much of the bone loss is attributable to
the BMT. In a smaller study, Castelo-Braco et al. [41]
re p o rted on 13 women 13 months (mean) after BMT. Eight
women underwent autotransplantation, and 5 received an
allotransplant. All 13 women were menopausal after BMT,
and none received HRT at the time of initial evaluation.
Nine of the 13 (70%) had evidence of osteopenia or osteo-
p o rosis in the lumbar vert e b r a e .
R e c e n t l y, we studied the incidence of decreased bone
mineral density among autotransplantation patients at our
institution [42]. We evaluated bone density at the lumbar
spine and femoral neck in 33 of 35 consecutive patients
( 1 7 women and 16 men) attending our Autotransplant
Long-term Follow-up Clinic. Patients, median age 50 years,
were evaluated a median of 4.4 years after autologous BMT.
At the lumbar spine, 11 of 33 patients (33%; 4 men and
7 women) had osteopenia, and 1 man (3%) had osteoporo s i s .
At the femoral neck, 15 patients (45%; 7 men and 8 women)
had osteopenia, and 5 (15%; 2 men and 3 women) had
o s t e o p o rosis. No patient sustained a bone fracture after
autotransplantation. By univariate and multivariate analysis,
only older age at evaluation was predictive of decre a s e d
bone density. Thus, most of our patients have decre a s e d
bone mineral density after autotransplantation, and men and
women are equally affected.
Ebeling et al. [21] followed bone density changes in 39
patients (19 women and 20 men) prospectively for 1 year
after auto- or allotransplantation. They compared bone
density before and after transplantation. Among the auto-
transplant recipients, bone density in the lumbar spine and
femur was essentially normal before transplantation and did
not decrease after BMT. In contrast, bone density was lower
among the allotransplant recipients before transplantation
and was decreased by 2% and 10% in the vertebrae and
femoral neck bone, respectively, 1 year after BMT. Bone loss
c o rrelated with cyclosporine use and the cumulative pre d-
nisone dose. The lack of osteopenia and osteoporosis among
autotransplantation patients stands in contrast to the other
re p o rts [40-43]. This diff e rence may be due in part to the
early use of estrogen replacement by Ebeling et al. [21]. All
women received HRT starting 2 months after autotrans-
plantation. The authors also did not comment on calcium
and vitamin D supplemental intake by their patients.
The risk of bone fracture after BMT is not well charac-
terized. Rib and vertebral fractures have been re p o rted as
ranging from 1% to 9% [21,39,43]. As the number of older
l o n g - t e rm BMT survivors increases, a greater appre c i a t i o n
of the incidence of osteoporosis-related bone fractures after
transplantation is likely.
EVALUATION OF BONE DENSITY
C u rre n t l y, bone density is typically evaluated by dual-
e n e rgy x-ray absorptiometry. In this pro c e d u re, a low-
intensity x-ray beam rapidly scans the desired sites. Based
on the amount of x-ray transmission through the bone,
the bone density is calculated. The bone density is com-
p a red with normal values from healthy young adults and
age- and sex-matched controls to derive the T and Z s c o re s ,
re s p e c t i v e l y. In practice, the most common sites for evalu-
ation are the femur and the lumbar spine. These sites are
chosen because they re p resent common sites of osteo-
p o rotic fractures. When interpreting the results of bone
density for the lumbar spine, it is important to re m e m b e r
that the bone density can be falsely elevated by degenera-
tive disease of the spine [44].
Bone turnover can be measured by serum and urine
markers such as urinary hydro x y p roline and serum osteocal-
cin. In postmenopausal women, biochemical markers of bone
metabolism have been shown to correlate with results of
bone densitometry [45,46]. These markers can also pre d i c t
who will respond to bisphosphonate treatment for osteo-
p o rosis [47]. Nonetheless, biochemical markers are not
widely used outside the re s e a rch setting. In part, the lack of
acceptance stems from a lack of consensus on when to ord e r
these tests and how to incorporate the results into tre a t m e n t
algorithms. Furt h e rm o re, these tests are expensive and can
be perf o rmed only in specialized laboratories. Curre n t l y,
these markers are not re q u i red and are not sufficient to diag-
nose osteoporosis or osteopenia. Since biochemical markers
of bone turnover identify patients at risk for bone loss before
changes in bone density occur, perhaps future patients will
be selected for treatment based on biochemical evidence of
bone turnover before there is any loss of bone density.
A.D. Schimmer et al.
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In the general population, the initial evaluation of
o s t e o p o rosis or osteopenia includes a screen for secondary
causes of osteoporosis (Table 2). Investigations include
m e a s u rement of serum calcium, alkaline phosphatase, and
t h y roid-stimulating hormone. A complete blood count
and serum immunoglobulins are also recommended. The
yield of these investigations among BMT survivors is
unknown, but it seems reasonable to order these tests to
define their usefulness.
TREATMENT AND PREVENTION
The treatment and prevention of osteoporosis include
lifestyle modifications and medical therapy. Patients should
be advised to stop smoking, reduce alcohol consumption,
and engage in regular low-impact exercise.
Most of the recommendations on the treatment and
prevention of osteoporosis are based on the general medical
literature. Few studies have examined the impact of medical
therapy on the prevention and treatment of osteoporo s i s
after BMT. Castelo-Braco et al. [41] evaluated the impact of
HRT on bone density after transplantation. They examined
the effects of HRT in 13 menopausal women after auto-
transplantation or allotransplantation. The median age of
the 13 women was 29.9 years. All patients had an increase in
their bone density at the lumbar spine after 1 year of HRT.
The median increase in bone density was 8.9%, with a range
of 0.65% to 11%. This study contained too few patients to
examine the impact of HRT on fracture rate after BMT.
However, a study in postmenopausal women demonstrated
that HRT increases mean bone density in the spine by
5.1%, which translated into a 39% risk reduction in fracture
rate [48]. The ideal time to commence HRT is within the
first 3 years of the onset of menopause, because this is the
period of most rapid bone loss [35,49]. The optimal dura-
tion of HRT is unknown, but whenever HRT is stopped,
the accelerated rate of bone loss re t u rns [48]. There f o re ,
lifelong replacement therapy might be required. Because all
women undergoing BMT become menopausal immediately
after transplantation, consideration should be given to start-
ing all women on HRT after transplantation.
A concern re g a rding HRT in this population is the
potentially increased risk of breast cancer. The studies on
the risk of breast cancer from HRT are contradictory, but
any increase in the risk of breast cancer is small [50-52].
Fortunately, BMT itself does not increase the risk of breast
cancer [53]. However, patients with a history of Hodgkin’s
disease and mantle radiation therapy already have a particu-
larly high risk, with a 35% lifetime risk of breast cancer [54].
For patients with a high risk for breast cancer, the selective
e s t rogen agonist raloxifene is an attractive alternative to
e s t rogen. Raloxifene increases bone density and does not
stimulate the proliferation of breast or endometrial tissue
[55,56]. Before raloxifene becomes more widely used, stud-
ies must show that it decreases fracture rate in addition to
increasing bone mineral density.
The effects of fluoride exemplify the importance of
demonstrating that a therapy decreases the fracture rate as
well as increases the bone mineral density. Fluoride stimu-
lates bone formation through an unknown mechanism. Flu-
oride supplementation results in large increases in bone
d e n s i t y, but it has little, if any, effect on the fracture rate
[57-59]. The reason for this discrepancy is unknown.
Because of its lack of benefit on fracture rate, fluoride is no
longer widely used in the treatment of osteoporosis.
Calcitonin is a peptide normally synthesized by the
t h y roid C cells. It inhibits osteoclasts and thereby decre a s e s
bone resorption [60]. In early postmenopausal women, the
intranasal form of calcitonin has not been shown to pre-
vent bone loss [61]. In 1 study in older postmenopausal
women, calcitonin decreased the number of fractures, but
the absolute number of fractures in the study was small
[62]. There f o re, because of the expense and questionable
benefit of calcitonin, it is not generally used for the pre-
vention or treatment of osteoporosis. It does, however,
have a role in the treatment of pain from an acute vert e b r a l
f r a c t u re [63].
D e ficiencies of calcium and vitamin D lead to incre a s e d
p a r a t h y roid hormone production and subsequent bone loss.
In a randomized trial of 389 healthy subjects older than
65 years, calcium and vitamin D supplementation incre a s e d
bone density and decreased the incidence of nonvertebral frac-
t u res [64]. Other studies have confirmed these findings [65].
Valimaki et al. [38] conducted a randomized trial of
calcium, calcium and intranasal calcitonin, or placebo in
61 adults after allotransplantation. Treatment was start e d
at the time of BMT and continued for 1 year. Compare d
with placebo, calcium with or without intranasal calcitonin
did not prevent bone loss after BMT. The lack of effect of
therapy in this trial may be multifactorial. First, most trials
that examine the effects of calcium on bone density also
include a supplement with vitamin D. Second, the women
in this trial did not receive HRT. Finally, the patients who
experienced GVHD re q u i red treatment with steroids. In
the face of steroid use and estrogen deficiency, calcium and
calcitonin may not be sufficient to prevent bone loss. To
Table 2 . Secondary Causes of Osteoporosis
Medications
Glucorticoids
Antiepileptic drugs
L-Thyroxine
Heparin
Endocrine disorders
Hyperparathyroidism
Hyperthyroidism
Cushing’s disease
Premature gonadal failure
Hematologic disorders
Multiple myeloma
Hodgkin’s disease
Non-Hodgkin’s lymphoma
Gastrointestinal disorders
Malabsorption syndromes
Chronic liver disease
Rheumatologic disorders
Rheumatoid arthritis
Ankylosing spondylitis
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date, only bisphosphonates have been shown to pre v e n t
s t e roid-induced bone loss [66].
Bisphosphonates are pyrophosphate analogs that inhibit
osteoclast function by increasing osteoclast apoptosis. Bis-
phosphonates decrease bone fractures and increase bone
density in patients with osteoporosis. In a randomized trial,
the bisphosphonate alendronate prevented bone loss and
d e c reased bone turnover in patients receiving long-term ,
low-dose glucocort i c o i d s [66]. Alendronate is poorly
absorbed and has a potentially serious side effect of severe
esophagitis [67]. Therefore, it must be taken with a full glass
of water 30 minutes before a meal. After taking alendronate,
the patients must then remain upright for 30 minutes.
E t i d ronate, a less potent bisphosphonate than alendro n a t e ,
also is widely used in the treatment of osteoporosis in the
general population. Like alendronate, etidronate incre a s e s
bone density in patients with osteoporosis [68,69]. Etidro-
nate is given in a cyclical schedule: 14 days of etidronate fol-
lowed by 76 days of calcium supplementation. The absorp-
tion of etidronate is reduced by calcium. There f o re, foods
with a high calcium content should not be consumed within
2 hours of taking etidronate.
CONCLUSION
Based on the available evidence, we make the following
recommendations to our patients re g a rding the tre a t m e n t
and prevention of osteoporosis (Table 3). We advocate early
detection and aggressive treatment to prevent osteoporosis.
We recommend that bone densitometry be perf o rmed as
part of the pretransplantation evaluation to assess the degree
of bone loss before transplantation. After transplantation,
we repeat the bone densitometry yearly for at least the first
2 years. In patients with decreased bone mineral density, we
continue yearly bone densitometry. In patients with well-
p re s e rved bone density, the densitometry can be re p e a t e d
every 3 to 5 years. However, the scans are obtained earlier if
the patient acquires new risks for bone loss.
Patients with a T score of –1 to –2.5 in either the
femur or the lumbar spine are off e red lifestyle counseling.
They are encouraged to quit smoking, adopt a high-calcium
diet, and commence regular low-impact exercise. In our
p rogram, lifestyle counseling is provided by the clinic
nurses. In other centers, special multidisciplinary osteo-
p o rosis clinics have been created, which include dietitians,
physical therapists, and pharmacists. For patients with
osteopenia, we recommend supplementation with calcium
(1500 mg/day) and vitamin D (400 IU/day). We also sug-
gest that menopausal women commence HRT. Wo m e n
who have a history of Hodgkin’s disease or mantle radia-
tion or who have an increased risk for breast cancer are
o ff e red raloxifene instead. Men with decreased testos-
t e rone are given testosterone replacement therapy either
intramuscularly or transderm a l l y. For patients with a T s c o re
less than –2.5, we offer the latter therapy in addition to
a l e n d ronate (10 mg/day). Patients with myeloma may sub-
stitute monthly intravenous pamidronate or daily oral clod-
ronate for alendronate. Both pamidronate and clodro n a t e
d e c rease skeletal events in patients with myeloma. The
choice between pamidronate and clodronate is mainly
d e t e rmined by availability and cost as well as by patient
and physician pre f e re n c e s .
In conclusion, osteopenia and osteoporosis are common
complications of BMT. Many patients have significant bone
loss before transplantation and experience further decreases
in bone density after transplantation. Since early re c o g n i-
tion and aggressive treatment of bone loss can prevent bone
fracture, we suggest that bone densitometry and aggressive
preventive therapy should be integral components to follow-
up of long-term BMT survivors.
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